Trademark Overview
On Thursday, March 22, 2018, a trademark application was filed for ESTEMIQ with the United States Patent and Trademark Office. The USPTO has given the ESTEMIQ trademark a serial number of 87844857. The federal status of this trademark filing is ABANDONED - EXPRESS as of Friday, September 14, 2018. This trademark is owned by Pfizer Inc.. The ESTEMIQ trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use; Pharmaceutical preparation for the management of vaso-occlusive crisis resulting from sickle cell anemia; pharmaceutical preparations to reduce blood cell adhesion, blood vessel blockage, pain and inflammation and to increase blood flow
